Article Information
History
- August 21, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Linxuan Wu1,
- David Kaftan2,
- Rachel Wittenauer3,
- Cory Arrouzet1,
- Nishali Patel4,5,
- Arden L. Saravis1,
- Brian Pfau1,
- Edinah Mudimu6,
- Anna Bershteyn2,¥ and
- Monisha Sharma4,*,¥
- 1Department of Epidemiology, University of Washington, Seattle, WA, USA
- 2Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA
- 3CHOICE Institute, University of Washington School of Pharmacy, Seattle, USA
- 4Department of Global Health, University of Washington, Seattle, WA, USA
- 5Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA
- 6Department of Decision Sciences, Pretoria, South Africa
- ↵*Corresponding author: Monisha Sharma, University of Washington, Box 359931, Seattle, WA 98195, United States. msharma1{at}uw.edu
Posted August 21, 2024.
Health and budget impact, and price threshold for cost-effectiveness of lenacapavir for PrEP in Eastern and Southern Africa: a modeling analysis
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos